JP2016512817A - 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ - Google Patents

高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ Download PDF

Info

Publication number
JP2016512817A
JP2016512817A JP2016500694A JP2016500694A JP2016512817A JP 2016512817 A JP2016512817 A JP 2016512817A JP 2016500694 A JP2016500694 A JP 2016500694A JP 2016500694 A JP2016500694 A JP 2016500694A JP 2016512817 A JP2016512817 A JP 2016512817A
Authority
JP
Japan
Prior art keywords
canagliflozin
probenecid
hyperuricemia
gout
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016500694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512817A5 (enExample
Inventor
ローゼンバーグ，ポール
ウェイズ，ダグラス．，ケー
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2016512817A publication Critical patent/JP2016512817A/ja
Publication of JP2016512817A5 publication Critical patent/JP2016512817A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016500694A 2013-03-15 2014-03-06 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ Withdrawn JP2016512817A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786738P 2013-03-15 2013-03-15
US61/786,738 2013-03-15
PCT/US2014/020958 WO2014149789A1 (en) 2013-03-15 2014-03-06 Combination of canagliflozin and probenecid for the treament of hyperuricemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019022272A Division JP2019089825A (ja) 2013-03-15 2019-02-12 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ

Publications (2)

Publication Number Publication Date
JP2016512817A true JP2016512817A (ja) 2016-05-09
JP2016512817A5 JP2016512817A5 (enExample) 2017-04-06

Family

ID=50483479

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016500694A Withdrawn JP2016512817A (ja) 2013-03-15 2014-03-06 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
JP2019022272A Pending JP2019089825A (ja) 2013-03-15 2019-02-12 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019022272A Pending JP2019089825A (ja) 2013-03-15 2019-02-12 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ

Country Status (6)

Country Link
US (2) US20160022632A1 (enExample)
EP (1) EP2968235B1 (enExample)
JP (2) JP2016512817A (enExample)
CA (1) CA2907079C (enExample)
ES (1) ES2647526T3 (enExample)
WO (1) WO2014149789A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087239A1 (ja) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート 腎症治療剤
JP2022510303A (ja) * 2018-12-06 2022-01-26 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置または予防するための方法
JP2023529691A (ja) * 2020-06-10 2023-07-11 アースローシ セラピューティクス，インク． 慢性腎疾患を処置または防止するための方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105548378B (zh) * 2015-12-03 2017-12-26 上海应用技术学院 一种卡格列净α、β异构体的分离方法
US11547685B2 (en) * 2017-12-11 2023-01-10 Mayo Foundation For Medical Education And Research Using probenecid to treat polycystic kidney disease
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
SG11202105745UA (en) 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Crystalline forms of a compound for treating or preventing gout or hyperuricemia
US20200253878A1 (en) 2019-02-13 2020-08-13 Iterum Therapeutics International Limited Combinations of beta-lactam compounds and probenecid and uses thereof
CN111057049B (zh) * 2019-11-18 2021-06-01 杭州华东医药集团新药研究院有限公司 一种卡格列净半水化合物的制备方法
CN112957318A (zh) * 2021-02-02 2021-06-15 河北科星药业有限公司 丙磺舒溶液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520965A (ja) * 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53365B (sr) 2003-08-01 2014-10-31 Mitsubishi Tanabe Pharma Corporation Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520965A (ja) * 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"日本における糖尿病治療への貢献をめざした戦略的提携について −2型糖尿病治療薬「MP-513」および「TA-728", 田辺三菱製薬ＨＰ ニュースリリース 2012年3月6日の報道関係者への書類, JPN7017004315, 6 March 2012 (2012-03-06), pages 1 - 2, ISSN: 0003891832 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087239A1 (ja) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート 腎症治療剤
JP2022510303A (ja) * 2018-12-06 2022-01-26 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置または予防するための方法
JP7528080B2 (ja) 2018-12-06 2024-08-05 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置または予防するための方法
JP2023529691A (ja) * 2020-06-10 2023-07-11 アースローシ セラピューティクス，インク． 慢性腎疾患を処置または防止するための方法

Also Published As

Publication number Publication date
WO2014149789A1 (en) 2014-09-25
EP2968235A1 (en) 2016-01-20
CA2907079C (en) 2021-06-22
US20170368025A1 (en) 2017-12-28
US20160022632A1 (en) 2016-01-28
ES2647526T3 (es) 2017-12-22
EP2968235B1 (en) 2017-09-13
JP2019089825A (ja) 2019-06-13
CA2907079A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
JP2016512817A (ja) 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
US20220152055A1 (en) Methods and compositions for treating various disorders
US20180161314A1 (en) Methods for Treating Hyperuricemia and Related Diseases
EP2552441B1 (en) Uses of dgat1 inhibitors
EP2582683B1 (en) Treatment of gout and hyperuricemia
TW201249432A (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN102802418A (zh) 用于治疗肌萎缩性侧索硬化的组合物和方法
US20180311217A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
HK1248124A1 (zh) 用於治疗肥胖症和肥胖症相关疾病的包含卡格列净和芬特明的协同治疗
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
JP2009532498A (ja) 有機化合物の組合せ
KR20150002799A (ko) 할로페네이트 또는 할로펜산 및 소염제를 이용한 통풍 환자에서의 고요산혈증 치료 방법
JP7668386B2 (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
TW202103709A (zh) 用於治療患有慢性腎臟病之對象的方法
JP2024538054A (ja) 高シュウ酸尿症及び腎結石の治療のための１ｈ－１，２，３－トリアゾール－４－カルボン酸

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190212

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190227

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190313